|Title:||Extended release formulation of nevirapine|
|Abstract:||The invention relates to an extended release pharmaceutical composition comprising nevirapine.|
|Inventor(s):||Cappola; Michael L. (Malvern, PA), Sienkiewicz; Svetlana (New Milford, CT), Snow; Glenn Charles (Sandy Hook, CT), Chen; Feng-Jing (Danbury, CT)|
|Assignee:||Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)|
|Patent Claims:||1. A method for treating HIV-1 infection which comprises once daily adminstration to a human infected by HIV-1 a tablet pharmaceutical dosage form wherein each tablet comprises: (a) 400 mg of anhydrous nevirapine; (b) 270 mg of Hypromellose 2208; (c) 400 mg of lactose monohydrate; and (d) 10 mg of Magnesium stearate; wherein each tablet is compressed by a force of 10-25 kN.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.